Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
$1.34
+0.8%
$1.32
$1.05
$10.16
$42.15M1.65183,994 shs66,454 shs
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
$3.03
+1.3%
$3.13
$1.75
$4.97
$41.90M1.0699,458 shs62,000 shs
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
$3.10
$3.10
$2.50
$13.00
$10.58M2.352,472 shsN/A
Pluri Inc. stock logo
PLUR
Pluri
$5.27
+1.9%
$5.14
$3.33
$7.13
$41.48M0.6913,286 shs10,776 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
0.00%+0.75%+6.35%+15.52%-85.88%
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
0.00%-6.77%+5.57%+7.45%+302,999,900.00%
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.00%0.00%0.00%0.00%0.00%
Pluri Inc. stock logo
PLUR
Pluri
0.00%-3.48%+2.13%+19.23%-7.54%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
2.7067 of 5 stars
3.53.00.00.02.71.70.6
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
2.4407 of 5 stars
3.50.00.00.02.60.81.3
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Pluri Inc. stock logo
PLUR
Pluri
2.3644 of 5 stars
3.53.00.00.02.71.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
3.00
Buy$17.571,211.30% Upside
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
3.00
Buy$12.00296.04% Upside
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.00
N/AN/AN/A
Pluri Inc. stock logo
PLUR
Pluri
3.00
Buy$12.00127.70% Upside

Current Analyst Ratings Breakdown

Latest PHXM, ACRV, GRCE, and PLUR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2025
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$9.00 ➝ $8.00
6/2/2025
Pluri Inc. stock logo
PLUR
Pluri
Industrial Alliance Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$12.00
6/2/2025
Pluri Inc. stock logo
PLUR
Pluri
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$12.00
(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
N/AN/AN/AN/A$5.68 per shareN/A
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/AN/AN/AN/A$4.86 per shareN/A
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
N/AN/AN/AN/A$7.98 per shareN/A
Pluri Inc. stock logo
PLUR
Pluri
$330K125.68N/AN/A$1.00 per share5.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
-$80.56M-$2.25N/AN/AN/AN/A-50.78%-46.08%11/12/2025 (Estimated)
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
-$9.57M-$0.86N/AN/AN/AN/A-20.36%-18.09%11/12/2025 (Estimated)
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
-$240KN/A0.00N/AN/AN/AN/AN/A
Pluri Inc. stock logo
PLUR
Pluri
-$20.89M-$5.53N/AN/A-2,563.29%-4,191.91%-85.40%9/17/2025 (Estimated)

Latest PHXM, ACRV, GRCE, and PLUR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/17/2025N/A
Pluri Inc. stock logo
PLUR
Pluri
-$0.73N/AN/AN/A$0.40 millionN/A
8/13/2025Q2 2025
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
-$0.57-$0.55+$0.02-$0.55N/AN/A
8/12/2025Q1 2026
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
-$0.22-$0.21+$0.01-$0.21N/AN/A
6/20/2025Q4 2025
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
-$0.23-$0.21+$0.02$0.01N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
N/AN/AN/AN/AN/A
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/AN/AN/AN/AN/A
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
N/AN/AN/AN/AN/A
Pluri Inc. stock logo
PLUR
Pluri
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
N/A
10.31
10.31
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/A
8.87
8.87
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.23
1.78
N/A
Pluri Inc. stock logo
PLUR
Pluri
51.65
4.81
4.81

Institutional Ownership

CompanyInstitutional Ownership
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
71.62%
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
6.08%
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.40%
Pluri Inc. stock logo
PLUR
Pluri
16.59%

Insider Ownership

CompanyInsider Ownership
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
8.50%
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
11.10%
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
1.94%
Pluri Inc. stock logo
PLUR
Pluri
25.93%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
5831.46 million28.78 millionNot Optionable
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/A13.83 million12.29 millionN/A
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
493.41 million3.35 millionNo Data
Pluri Inc. stock logo
PLUR
Pluri
1507.87 million5.83 millionOptionable

Recent News About These Companies

Reviewing Pluri (NASDAQ:PLUR) and Medicus Pharma (NASDAQ:MDCX)
Pluri Inc. reschedules 2025 annual meeting
Pluri: Fiscal Q3 Earnings Snapshot
Pluri Inc. acquires majority stake in Kokomodo Ltd.
Pluri acquires 71% stake in Kokomodo
Pluri’s immune cell expansion technologies gain patents

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acrivon Therapeutics stock logo

Acrivon Therapeutics NASDAQ:ACRV

$1.34 +0.01 (+0.75%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$1.35 +0.01 (+0.75%)
As of 08/29/2025 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Grace Therapeutics stock logo

Grace Therapeutics NASDAQ:GRCE

$3.03 +0.04 (+1.34%)
As of 08/29/2025 04:00 PM Eastern

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

PHAXIAM Therapeutics stock logo

PHAXIAM Therapeutics NASDAQ:PHXM

$3.10 0.00 (0.00%)
As of 08/29/2025

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Pluri stock logo

Pluri NASDAQ:PLUR

$5.27 +0.10 (+1.93%)
Closing price 08/29/2025 03:59 PM Eastern
Extended Trading
$5.58 +0.31 (+5.88%)
As of 08/29/2025 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.